Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Precigen Q3 2026 Results: Turns Profitable, Net Income $35.8M

Precigen, Inc. reported a significant increase in total revenues to $152.4 million for the nine months ended September 30, 2026, primarily driven by $148.0 million in net product revenues following the commercialization of Papzimeos. The company achieved a net profit for the period, reducing its accumulated deficit to $2.29 billion, while maintaining a cash and short-term investment position of approximately $46.1 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue74.12.9
Profit before tax36.0-146.3
Net income35.8-146.3
EPS (diluted, $ a share)$0.08$-1.06

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+2437.6%
Operating margin52.1%
Source

10-Q filed with the SEC, NASDAQ: PGEN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Precigen, Inc.: key numbers

Share price
$4.30Close, Nov 16
Market cap
$1.54B
Shares outstanding
358.55MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Precigen, Inc.

All →
6:03 AM ET 8-K
Financial Results

Precigen Financial Results

Precigen reported third quarter 2026 financial results, highlighted by $72.9 million in PAPZIMEOS net revenue, a 37% sequential increase. The company achieved positive cash flow a full quarter ahead of guidance and reported net income of $35.8 million, driven by strong commercial adoption of its RRP treatment.

Term
Q3 2026

“Precigen has established an exceptional position of strength, with commercial momentum and a proven strategy driving our next phase of growth. PAPZIMEOS has transformed treatment for adults with RRP, with well over 500 patients initiating treatment and 300 of them having completed treatment demonstrating recognition as the first-line standard of care.”

Helen Sabzevari, PhD, President and CEO of Precigen

“PAPZIMEOS net revenue grew 37% quarter-over-quarter to $72.9 million, demonstrating the strength of our commercial execution and growing demand for the first FDA-approved therapy for adults with RRP.”

Phil Tennant, Chief Commercial Officer of Precigen

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.